- $35.79m
- -$116.32m
- 18
- 54
- 19
- 20
Annual balance sheet for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 73 | 66.7 | 121 | 152 |
| Prepaid Expenses | ||||
| Total Current Assets | 74.6 | 68 | 124 | 154 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 3.1 | 7.73 | 4.58 | 51.4 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 114 | 76.8 | 130 | 206 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 3.87 | 7.73 | 9.36 | 8.13 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 3.96 | 10.6 | 9.36 | 55.8 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Total Equity | 110 | 66.3 | 121 | 151 |
| Total Liabilities & Shareholders' Equity | 114 | 76.8 | 130 | 206 |
| Total Common Shares Outstanding |